Chiara Mercinelli

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Journal: Expert review of anticancer therapy

Published: June 30, 2026

PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

Journal: European urology oncology

Published: June 03, 2026

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 31, 2026

Prognostic Impact of Initial Management Strategies in Metachronous Oligometastatic Renal Cell Carcinoma: A Real-World Evidence.

Prognostic Impact of Initial Management Strategies in Metachronous Oligometastatic Renal Cell Carcinoma: A Real-World Evidence.

Journal: Clinical genitourinary cancer

Published: May 11, 2026

Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter.

Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter.

Journal: Clinical genitourinary cancer

Published: May 07, 2026

Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy.

Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy.

Journal: Clinical genitourinary cancer

Published: May 03, 2026

Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials.

Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials.

Journal: ESMO open

Published: April 13, 2026

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Journal: Frontiers in immunology

Published: February 26, 2026

Real-world overall survival improvements in metastatic urothelial carcinoma across three key therapeutic temporal periods.

Real-world overall survival improvements in metastatic urothelial carcinoma across three key therapeutic temporal periods.

Journal: ESMO open

Published: February 22, 2026

Corrigendum to "Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials" [Eur. Urol. (2025)].

Corrigendum to "Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials" [Eur. Urol. (2025)].

Journal: European urology

Published: February 18, 2026

Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study.

Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study.

Journal: Clinical genitourinary cancer

Published: January 14, 2026

Re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.

Re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.

Journal: European urology

Published: January 01, 2026

Showing 1-12 of 60

Last Updated: 09/26/2026